Trial Profile

A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liafensine (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Acronyms BMS TRUI
Sponsors Bristol-Myers Squibb

Most Recent Events

01 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
13 Sep 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
24 Jul 2012 New source identified and integrated (Clinical Trials Registry - India, CTRI2012-07-002773).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com